South & Central America Epilepsy Market Forecast to 2030 - Regional Analysis - by Type, Route of Administration, Treatment Type, Age Group, and Distribution Channel

List of Tables

The South & Central America epilepsy market was valued at US$ 593.56 million in 2022 and is expected to reach US$ 758.65 million by 2030; it is estimated to register a CAGR of 3.1% from 2022 to 2030.

Surge in Awareness Programs Conducted by Organizations Fuels South & Central America Epilepsy Market

Growing awareness about epilepsy, its symptoms, and the importance of early diagnosis has led to a surge in patients seeking medical attention. Organizations such as the Epilepsy Foundation, Epilepsy Society, the American Epilepsy Society, and the Epilepsy Association of Central Florida play a crucial role in educating people about this disease. The involvement of these organizations has resulted in increased rates of diagnosis and a broader patient population requiring epilepsy treatment. Numerous awareness campaigns are conducted by organizations worldwide to spread awareness regarding the condition and available treatment. In Brazil, the Brazilian League of Epilepsy (LBE) conducts nationwide awareness campaigns during Epilepsy Awareness Month. They organize events, distribute educational materials, and collaborate with media outlets to raise awareness about epilepsy and reduce stigma. Thus, such initiatives and awareness campaigns result in an increase in epilepsy diagnoses and treatments, offering lucrative growth opportunities to the market.

South & Central America Epilepsy Market Overview

The epilepsy market in South & Central America includes a country-level analysis of Brazil, Argentina, and the Rest of South & Central America. Brazil is expected to have a significant market share in this region. According to the Pan American Health Organization, there is a treatment gap in Latin America, South America, and the Caribbean, i.e., is over 50%. In recent years, countries have strengthened their focus on noncommunicable diseases, including epilepsy. According to the International Journal of Public Health article published in 2023, a total of 1,375,066 disability-adjusted life years (DALYs) in South & Central America countries were attributed to epilepsy in 2019, with men being more affected.

South & Central America Epilepsy Market Revenue and Forecast to 2030 (US$ Million)

South & Central America Epilepsy Market Segmentation

The South & Central America epilepsy market is categorized into type, route of administration, treatment type, age group, distribution channel, and country.

Based on type, the South & Central America epilepsy market is categorized into progressive myoclonic epilepsy, reflex epilepsy, generalized epilepsy, and other. The generalized epilepsy segment held the largest market share in 2022.

In terms of route of administration, the South & Central America epilepsy market is categorized into oral, parenteral, and others. The oral segment held the largest market share in 2022.

By treatment type, the South & Central America epilepsy market is segmented into first generation drugs, second generation drugs, and third generation drugs. The third generation drugs segment held the largest market share in 2022.

Based on age group, the South & Central America epilepsy market is bifurcated into adult and children. The adult segment held a larger market share in 2022.

In terms of distribution channel, the South & Central America epilepsy market is categorized into hospital pharmacies, retail pharmacies, and others. The hospital pharmacies segment held the largest market share in 2022.

By country, the South & Central America epilepsy market is segmented into Brazil, Argentina, and the Rest of South & Central America. Brazil dominated the South & Central America epilepsy market share in 2022.

Abbott Laboratories, Pfizer Inc, Eisai Co Ltd, UCB SA, LivaNova Plc, Novartis AG, Medtronic Plc, GSK Plc, and H. Lundbeck AS are some of the leading companies operating in the South & Central America epilepsy market.

Product Code: BMIRE00030802

1. Introduction

1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation

2. Executive Summary

2.1 Key Insights
2.2 Market Attractiveness

3. Research Methodology

3.1 Coverage
3.2 Secondary Research
3.3 Primary Research

4. Pipeline Studies for Epilepsy Therapy Approaches

4.1 Pipeline Studies for Epilepsy Therapy Approaches
- 4.1.1 Cell and Gene Therapy Approaches
- 4.1.2 Encapsulated cell bio delivery (ECB) system
- 4.1.3 Gene Therapy for Epilepsy Clinical Overview
  - 4.1.3.1 Genetic Therapies Adopted for Clinic Research of Epilepsy
    - 4.1.3.1.1 Gene Supplementation - Overview
    - 4.1.3.1.2 Gene Modulation - Overview
    - 4.1.3.1.3 Antisense Oligonucleotides and RNA Interference - Overview
    - 4.1.3.1.4 Neuropeptides - Overview
    - 4.1.3.1.5 Engineered Channels - Overview
    - 4.1.3.1.6 Endogenous Channels - Overview
  - 4.1.3.2 Pipeline Studies of Viral Vectors for Epilepsy
  - 4.1.3.3 Pipeline Studies of Non-Viral Vectors for Epilepsy
    - 4.1.3.3.1 Polymer-based Non-Viral Vectors for Epilepsy
    - 4.1.3.3.2 Lipid-based Non-Viral Vectors for Epilepsy
  - 4.1.3.4 Adeno-Associated Virus (AAV)-Mediated Neuromodulatory Peptides - Overview
  - 4.1.3.5 Neurotrophic Factors for Gene Therapy Approaches
  - 4.1.3.6 Potassium Channels for Human Epileptic Phenotypes
  - 4.1.3.7 Enzyme Inducing Antiepileptic Drugs

5. South & Central America Epilepsy Market - Key Market Dynamics

5.1 Market Drivers
- 5.1.1 Rising Prevalence of Epilepsy
- 5.1.2 Increasing Investments in Development of Epilepsy Therapies
5.2 Market Restraints
- 5.2.1 Recall of Products
5.3 Market Opportunities
- 5.3.1 Surge in Awareness Programs Conducted by Organizations
5.4 Future Trends
- 5.4.1 Gene Therapy as Promising Treatment Approach
5.5 Impact of Drivers and Restraints:

6. Epilepsy Market - South & Central America Analysis

6.1 South & Central America: Epilepsy Market

7. South & Central America Epilepsy Market Analysis - by Type

7.1 Overview
7.2 Progressive Myoclonic Epilepsy
- 7.2.1 Overview
- 7.2.2 Progressive Myoclonic Epilepsy: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
7.3 Reflex Epilepsy
- 7.3.1 Overview
- 7.3.2 Reflex Epilepsy: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
7.4 Generalized Epilepsy
- 7.4.1 Overview
- 7.4.2 Generalized Epilepsy: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
7.5 Other
- 7.5.1 Overview
- 7.5.2 Other: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

8. South & Central America Epilepsy Market Analysis - by Route of Administration

8.1 Overview
8.2 Oral
- 8.2.1 Overview
- 8.2.2 Oral: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
8.3 Parenteral
- 8.3.1 Overview
- 8.3.2 Parenteral: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
8.4 Others
- 8.4.1 Overview
- 8.4.2 Others: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

9. South & Central America Epilepsy Market Analysis - by Treatment Type

9.1 Overview
9.2 First Generation Drugs
- 9.2.1 Overview
- 9.2.2 First Generation Drugs: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
9.3 Second Generation Drugs
- 9.3.1 Overview
- 9.3.2 Second Generation Drugs: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
9.4 Third Generation Drugs
- 9.4.1 Overview
- 9.4.2 Third Generation Drugs: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

10. South & Central America Epilepsy Market Analysis - by Age Group

10.1 Overview
10.2 Adult
- 10.2.1 Overview
- 10.2.2 Adult: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
10.3 Children
- 10.3.1 Overview
- 10.3.2 Children: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

11. South & Central America Epilepsy Market Analysis - by Distribution Channel

11.1 Overview
11.2 Hospital Pharmacies
- 11.2.1 Overview
- 11.2.2 Hospital Pharmacies: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
11.3 Retail Pharmacies
- 11.3.1 Overview
- 11.3.2 Retail Pharmacies: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
11.4 Others
- 11.4.1 Overview
- 11.4.2 Others: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

12. South & Central America Epilepsy Market - Country Analysis

12.1 South & Central America Epilepsy Market Overview
- 12.1.1 South & Central America: Epilepsy Market Breakdown, by Key Country, 2022 and 2030 (%)
  - 12.1.1.1 Brazil: Epilepsy Market Overview
  - 12.1.1.2 Brazil: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
    - 12.1.1.2.1 Brazil: Epilepsy Market Breakdown, by Type
    - 12.1.1.2.2 Brazil: Epilepsy Market Breakdown, by Route of Administration
    - 12.1.1.2.3 Brazil: Epilepsy Market Breakdown, by Treatment Type
    - 12.1.1.2.4 Brazil: Epilepsy Market Breakdown, by Age Group
    - 12.1.1.2.5 Brazil: Epilepsy Market Breakdown, by Distribution Channel
  - 12.1.1.3 Argentina: Epilepsy Market Overview
  - 12.1.1.4 Argentina: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
    - 12.1.1.4.1 Argentina: Epilepsy Market Breakdown, by Type
    - 12.1.1.4.2 Argentina: Epilepsy Market Breakdown, by Route of Administration
    - 12.1.1.4.3 Argentina: Epilepsy Market Breakdown, by Treatment Type
    - 12.1.1.4.4 Argentina: Epilepsy Market Breakdown, by Age Group
    - 12.1.1.4.5 Argentina: Epilepsy Market Breakdown, by Distribution Channel
  - 12.1.1.5 Rest of South & Central America: Epilepsy Market Overview
  - 12.1.1.6 Rest of South & Central America: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
    - 12.1.1.6.1 Rest of South & Central America: Epilepsy Market Breakdown, by Type
    - 12.1.1.6.2 Rest of South & Central America: Epilepsy Market Breakdown, by Route of Administration
    - 12.1.1.6.3 Rest of South & Central America: Epilepsy Market Breakdown, by Treatment Type
    - 12.1.1.6.4 Rest of South & Central America: Epilepsy Market Breakdown, by Age Group
    - 12.1.1.6.5 Rest of South & Central America: Epilepsy Market Breakdown, by Distribution Channel

13. Industry Landscape

13.1 Overview
13.2 Growth Strategies in Epilepsy Market
13.3 Organic Growth Strategies
- 13.3.1 Overview
13.4 Inorganic Growth Strategies
- 13.4.1 Overview

14. Company Profiles

14.1 Abbott Laboratories
- 14.1.1 Key Facts
- 14.1.2 Business Description
- 14.1.3 Products and Services
- 14.1.4 Financial Overview
- 14.1.5 SWOT Analysis
- 14.1.6 Key Developments
14.2 Pfizer Inc
- 14.2.1 Key Facts
- 14.2.2 Business Description
- 14.2.3 Products and Services
- 14.2.4 Financial Overview
- 14.2.5 SWOT Analysis
- 14.2.6 Key Developments
14.3 Eisai Co Ltd
- 14.3.1 Key Facts
- 14.3.2 Business Description
- 14.3.3 Products and Services
- 14.3.4 Financial Overview
- 14.3.5 SWOT Analysis
- 14.3.6 Key Developments
14.4 UCB SA
- 14.4.1 Key Facts
- 14.4.2 Business Description
- 14.4.3 Products and Services
- 14.4.4 Financial Overview
- 14.4.5 SWOT Analysis
- 14.4.6 Key Developments
14.5 LivaNova Plc
- 14.5.1 Key Facts
- 14.5.2 Business Description
- 14.5.3 Products and Services
- 14.5.4 Financial Overview
- 14.5.5 SWOT Analysis
- 14.5.6 Key Developments
14.6 Novartis AG
- 14.6.1 Key Facts
- 14.6.2 Business Description
- 14.6.3 Products and Services
- 14.6.4 Financial Overview
- 14.6.5 SWOT Analysis
- 14.6.6 Key Developments
14.7 Medtronic Plc
- 14.7.1 Key Facts
- 14.7.2 Business Description
- 14.7.3 Products and Services
- 14.7.4 Financial Overview
- 14.7.5 SWOT Analysis
- 14.7.6 Key Developments
14.8 GSK Plc
- 14.8.1 Key Facts
- 14.8.2 Business Description
- 14.8.3 Products and Services
- 14.8.4 Financial Overview
- 14.8.5 SWOT Analysis
- 14.8.6 Key Developments
14.9 H. Lundbeck AS
- 14.9.1 Key Facts
- 14.9.2 Business Description
- 14.9.3 Products and Services
- 14.9.4 Financial Overview
- 14.9.5 SWOT Analysis
- 14.9.6 Key Developments

15. Appendix

15.1 About The Insight Partners